Because our discovered G9a-translational mechanism directly and ultimately determined AD-correlated proteomic or phosphoproteomic changes in diseased brain, MS1262 showed high specificity and efficacy for protecting AD patients from cognitive impairment and noncognitive disorders. Here, EHMT2 is linked to Cognitive impairment.